Does the media refer more to HAE or IART?

In the previous week, Integra LifeSciences had 19 more articles in the media than Haemonetics. MarketBeat recorded 24 mentions for Integra LifeSciences and 5 mentions for Haemonetics. Haemonetics' average media sentiment score of 0.27 beat Integra LifeSciences' score of 0.08 indicating that Haemonetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Integra LifeSciences 1 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 8 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to IART or ITGR?

In the previous week, Integra LifeSciences had 18 more articles in the media than Integer. MarketBeat recorded 24 mentions for Integra LifeSciences and 6 mentions for Integer. Integer's average media sentiment score of 0.40 beat Integra LifeSciences' score of 0.08 indicating that Integer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integra LifeSciences 1 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 8 Negative mention(s) 0 Very Negative mention(s) Neutral Integer 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LIVN or IART?

In the previous week, Integra LifeSciences had 22 more articles in the media than LivaNova. MarketBeat recorded 24 mentions for Integra LifeSciences and 2 mentions for LivaNova. LivaNova's average media sentiment score of 0.34 beat Integra LifeSciences' score of 0.08 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Integra LifeSciences 1 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 8 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IART or IRTC?

In the previous week, Integra LifeSciences had 19 more articles in the media than iRhythm Technologies. MarketBeat recorded 24 mentions for Integra LifeSciences and 5 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 0.13 beat Integra LifeSciences' score of 0.08 indicating that iRhythm Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integra LifeSciences 1 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 8 Negative mention(s) 0 Very Negative mention(s) Neutral iRhythm Technologies 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IART or PLSE?

In the previous week, Integra LifeSciences had 21 more articles in the media than Pulse Biosciences. MarketBeat recorded 24 mentions for Integra LifeSciences and 3 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.44 beat Integra LifeSciences' score of 0.08 indicating that Pulse Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integra LifeSciences 1 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 8 Negative mention(s) 0 Very Negative mention(s) Neutral Pulse Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Integra LifeSciences (IART) Competitors

$12.68 -3.41 (-21.19%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$12.85 +0.17 (+1.33%)

As of 10/2/2026 07:56 PM Eastern

Compare

IART vs. HAE, ITGR, LIVN, IRTC, and PLSE

Should you buy Integra LifeSciences stock or one of its competitors? Integra LifeSciences's main competitors and comparable companies include Haemonetics (HAE), Integer (ITGR), LivaNova (LIVN), iRhythm Technologies (IRTC), and Pulse Biosciences (PLSE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Integra LifeSciences compare to Haemonetics?

Haemonetics (NYSE:HAE) and Integra LifeSciences (NASDAQ:IART) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Haemonetics currently has a consensus target price of $99.78, indicating a potential downside of 4.77%. Integra LifeSciences has a consensus target price of $18.43, indicating a potential upside of 45.34%. Given Integra LifeSciences' higher possible upside, analysts plainly believe Integra LifeSciences is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
Integra LifeSciences	2 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.88

99.7% of Haemonetics shares are held by institutional investors. Comparatively, 84.8% of Integra LifeSciences shares are held by institutional investors. 2.1% of Haemonetics shares are held by insiders. Comparatively, 3.8% of Integra LifeSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Integra LifeSciences had 19 more articles in the media than Haemonetics. MarketBeat recorded 24 mentions for Integra LifeSciences and 5 mentions for Haemonetics. Haemonetics' average media sentiment score of 0.27 beat Integra LifeSciences' score of 0.08 indicating that Haemonetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Integra LifeSciences	1 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	8 Negative mention(s)	0 Very Negative mention(s)	Neutral

Haemonetics has a net margin of 7.12% compared to Integra LifeSciences' net margin of -0.44%. Haemonetics' return on equity of 27.55% beat Integra LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.12%	27.55%	9.65%
Integra LifeSciences	-0.44%	18.30%	5.30%

Haemonetics has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Integra LifeSciences has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market.

Haemonetics has higher earnings, but lower revenue than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	3.57	$97.31M	$2.04	51.36
Integra LifeSciences	$1.64B	0.60	-$516.47M	-$0.09	N/A

Summary

Haemonetics beats Integra LifeSciences on 12 of the 17 factors compared between the two stocks.

How does Integra LifeSciences compare to Integer?

Integra LifeSciences (NASDAQ:IART) and Integer (NYSE:ITGR) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

In the previous week, Integra LifeSciences had 18 more articles in the media than Integer. MarketBeat recorded 24 mentions for Integra LifeSciences and 6 mentions for Integer. Integer's average media sentiment score of 0.40 beat Integra LifeSciences' score of 0.08 indicating that Integer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integra LifeSciences	1 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	8 Negative mention(s)	0 Very Negative mention(s)	Neutral
Integer	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Integra LifeSciences has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market. Comparatively, Integer has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

84.8% of Integra LifeSciences shares are owned by institutional investors. Comparatively, 99.3% of Integer shares are owned by institutional investors. 3.8% of Integra LifeSciences shares are owned by company insiders. Comparatively, 1.1% of Integer shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Integra LifeSciences currently has a consensus price target of $18.43, indicating a potential upside of 45.34%. Integer has a consensus price target of $109.86, indicating a potential downside of 13.13%. Given Integra LifeSciences' higher possible upside, analysts clearly believe Integra LifeSciences is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integra LifeSciences	2 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.88
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07

Integer has a net margin of 6.97% compared to Integra LifeSciences' net margin of -0.44%. Integra LifeSciences' return on equity of 18.30% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integra LifeSciences	-0.44%	18.30%	5.30%
Integer	6.97%	12.79%	6.48%

Integer has higher revenue and earnings than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integra LifeSciences	$1.64B	0.60	-$516.47M	-$0.09	N/A
Integer	$1.85B	2.32	$102.81M	$3.66	34.55

Summary

Integer beats Integra LifeSciences on 10 of the 15 factors compared between the two stocks.

How does Integra LifeSciences compare to LivaNova?

LivaNova (NASDAQ:LIVN) and Integra LifeSciences (NASDAQ:IART) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

LivaNova has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Integra LifeSciences has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market.

LivaNova has higher earnings, but lower revenue than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	2.98	-$242.47M	$3.38	22.21
Integra LifeSciences	$1.64B	0.60	-$516.47M	-$0.09	N/A

In the previous week, Integra LifeSciences had 22 more articles in the media than LivaNova. MarketBeat recorded 24 mentions for Integra LifeSciences and 2 mentions for LivaNova. LivaNova's average media sentiment score of 0.34 beat Integra LifeSciences' score of 0.08 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Integra LifeSciences	1 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	8 Negative mention(s)	0 Very Negative mention(s)	Neutral

LivaNova currently has a consensus target price of $84.13, suggesting a potential upside of 12.06%. Integra LifeSciences has a consensus target price of $18.43, suggesting a potential upside of 45.34%. Given Integra LifeSciences' higher probable upside, analysts clearly believe Integra LifeSciences is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55
Integra LifeSciences	2 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.88

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 84.8% of Integra LifeSciences shares are owned by institutional investors. 0.4% of LivaNova shares are owned by insiders. Comparatively, 3.8% of Integra LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

LivaNova has a net margin of 12.82% compared to Integra LifeSciences' net margin of -0.44%. Integra LifeSciences' return on equity of 18.30% beat LivaNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
Integra LifeSciences	-0.44%	18.30%	5.30%

Summary

LivaNova beats Integra LifeSciences on 10 of the 16 factors compared between the two stocks.

How does Integra LifeSciences compare to iRhythm Technologies?

Integra LifeSciences (NASDAQ:IART) and iRhythm Technologies (NASDAQ:IRTC) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Integra LifeSciences currently has a consensus price target of $18.43, indicating a potential upside of 45.34%. iRhythm Technologies has a consensus price target of $179.93, indicating a potential upside of 63.02%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, analysts plainly believe iRhythm Technologies is more favorable than Integra LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integra LifeSciences	2 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.88
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

In the previous week, Integra LifeSciences had 19 more articles in the media than iRhythm Technologies. MarketBeat recorded 24 mentions for Integra LifeSciences and 5 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 0.13 beat Integra LifeSciences' score of 0.08 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integra LifeSciences	1 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	8 Negative mention(s)	0 Very Negative mention(s)	Neutral
iRhythm Technologies	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

84.8% of Integra LifeSciences shares are owned by institutional investors. 3.8% of Integra LifeSciences shares are owned by company insiders. Comparatively, 1.0% of iRhythm Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Integra LifeSciences has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

Integra LifeSciences has a net margin of -0.44% compared to iRhythm Technologies' net margin of -1.69%. Integra LifeSciences' return on equity of 18.30% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integra LifeSciences	-0.44%	18.30%	5.30%
iRhythm Technologies	-1.69%	10.11%	1.53%

iRhythm Technologies has lower revenue, but higher earnings than Integra LifeSciences. iRhythm Technologies is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integra LifeSciences	$1.64B	0.60	-$516.47M	-$0.09	N/A
iRhythm Technologies	$747.14M	4.87	-$44.55M	-$0.43	N/A

Summary

Integra LifeSciences beats iRhythm Technologies on 9 of the 17 factors compared between the two stocks.

How does Integra LifeSciences compare to Pulse Biosciences?

Integra LifeSciences (NASDAQ:IART) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, Integra LifeSciences had 21 more articles in the media than Pulse Biosciences. MarketBeat recorded 24 mentions for Integra LifeSciences and 3 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.44 beat Integra LifeSciences' score of 0.08 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integra LifeSciences	1 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	8 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pulse Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pulse Biosciences has lower revenue, but higher earnings than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integra LifeSciences	$1.64B	0.60	-$516.47M	-$0.09	N/A
Pulse Biosciences	$350K	9,689.49	-$72.78M	-$1.18	N/A

Integra LifeSciences has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

84.8% of Integra LifeSciences shares are held by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are held by institutional investors. 3.8% of Integra LifeSciences shares are held by insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Integra LifeSciences has a net margin of -0.44% compared to Pulse Biosciences' net margin of -6,755.78%. Integra LifeSciences' return on equity of 18.30% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integra LifeSciences	-0.44%	18.30%	5.30%
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

Integra LifeSciences currently has a consensus price target of $18.43, suggesting a potential upside of 45.34%. Pulse Biosciences has a consensus price target of $50.20, suggesting a potential upside of 4.80%. Given Integra LifeSciences' higher probable upside, equities research analysts plainly believe Integra LifeSciences is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integra LifeSciences	2 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.88
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Pulse Biosciences beats Integra LifeSciences on 9 of the 17 factors compared between the two stocks.

Get Integra LifeSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IART and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IART vs. The Competition

Export

Metric	Integra LifeSciences	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$986.16M	$5.48B	$7.17B	$13.28B
Dividend Yield	N/A	1.79%	2.53%	17.33%
P/E Ratio	-140.87	25.42	274.69	26.04
Price / Sales	0.60	67.96	610.13	92.02
Price / Cash	3.00	32.73	27.22	34.69
Price / Book	0.95	5.92	10.97	6.34
Net Income	-$516.47M	$147.52M	$3.50B	$381.73M
7 Day Performance	-21.34%	-1.71%	-2.00%	-1.66%
1 Month Performance	-24.16%	-4.87%	-6.19%	-4.68%
1 Year Performance	-14.32%	1.30%	8.03%	1.57%

Integra LifeSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IART Integra LifeSciences	3.8029 of 5 stars	$12.68 -21.2%	$18.43 +45.3%	-14.3%	$986.16M	$1.64B	N/A	4,427	Trending News Analyst Upgrade Gap Down High Trading Volume
HAE Haemonetics	1.6707 of 5 stars	$105.66 -0.1%	$99.78 -5.6%	+107.9%	$4.81B	$1.33B	51.81	3,009	News Coverage
ITGR Integer	2.2826 of 5 stars	$126.32 0.0%	$109.86 -13.0%	+20.2%	$4.29B	$1.85B	34.51	11,000
LIVN LivaNova	2.7745 of 5 stars	$76.24 -1.3%	$84.13 +10.3%	+40.7%	$4.20B	$1.39B	22.56	3,300
IRTC iRhythm Technologies	3.4409 of 5 stars	$111.79 -0.7%	$179.93 +61.0%	-37.2%	$3.69B	$747.14M	N/A	2,400	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IART) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Integra LifeSciences (IART) Competitors

IART vs. HAE, ITGR, LIVN, IRTC, and PLSE

How does Integra LifeSciences compare to Haemonetics?

Summary

How does Integra LifeSciences compare to Integer?

Summary

How does Integra LifeSciences compare to LivaNova?

Summary

How does Integra LifeSciences compare to iRhythm Technologies?

Summary

How does Integra LifeSciences compare to Pulse Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IART vs. The Competition

Integra LifeSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Integra LifeSciences (IART) Competitors

IART vs. HAE, ITGR, LIVN, IRTC, and PLSE

How does Integra LifeSciences compare to Haemonetics?

Do analysts rate HAE or IART?

Do institutionals and insiders have more ownership in HAE or IART?

Does the media refer more to HAE or IART?

Is HAE or IART more profitable?

Which has more volatility & risk, HAE or IART?

Which has preferable valuation and earnings, HAE or IART?

Summary

How does Integra LifeSciences compare to Integer?

Does the media refer more to IART or ITGR?

Which has more volatility & risk, IART or ITGR?

Do insiders and institutionals believe in IART or ITGR?

Do analysts rate IART or ITGR?

Is IART or ITGR more profitable?

Which has stronger valuation & earnings, IART or ITGR?

Summary

How does Integra LifeSciences compare to LivaNova?

Which has more volatility and risk, LIVN or IART?

Which has stronger valuation & earnings, LIVN or IART?

Does the media prefer LIVN or IART?

Do analysts prefer LIVN or IART?

Do insiders and institutionals hold more shares of LIVN or IART?

Is LIVN or IART more profitable?

Summary

How does Integra LifeSciences compare to iRhythm Technologies?

Do analysts recommend IART or IRTC?

Does the media favor IART or IRTC?

Do insiders & institutionals have more ownership in IART or IRTC?

Which has more volatility and risk, IART or IRTC?

Is IART or IRTC more profitable?

Which has higher valuation and earnings, IART or IRTC?

Summary

How does Integra LifeSciences compare to Pulse Biosciences?

Does the media favor IART or PLSE?

Which has stronger earnings and valuation, IART or PLSE?

Which has more volatility & risk, IART or PLSE?

Do insiders and institutionals hold more shares of IART or PLSE?

Is IART or PLSE more profitable?

Do analysts recommend IART or PLSE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IART vs. The Competition

Integra LifeSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools